| Company Name: |
PharmaBlock Sciences (Nanjing), Inc.
|
| Tel: |
4000255188 |
| Email: |
sun_dan@PharmaBlock.com |
| Products Intro: |
Product Name:(3R)-3-(4,4-difluoro-1-piperidyl)-3-(4-hydroxyphenyl)-7-(trifluoromethyl)indolin-2-one
CAS:2768139-76-8
Purity:97% Package:1G;5G;10G;100G;250G
|
|
| | 2H-Indol-2-one, 3-(4,4-difluoro-1-piperidinyl)-1,3-dihydro-3-(4-hydroxyphenyl)-7-(trifluoromethyl)-, (3R)- Basic information |
| | 2H-Indol-2-one, 3-(4,4-difluoro-1-piperidinyl)-1,3-dihydro-3-(4-hydroxyphenyl)-7-(trifluoromethyl)-, (3R)- Chemical Properties |
| Boiling point | 485.1±45.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 9?+-.0.30(Predicted) | | form | Solid | | color | White to pink |
| | 2H-Indol-2-one, 3-(4,4-difluoro-1-piperidinyl)-1,3-dihydro-3-(4-hydroxyphenyl)-7-(trifluoromethyl)-, (3R)- Usage And Synthesis |
| Biological Activity | ErSO-DFP is an anticipatory unfolded protein response (a-UPR) activator. ErSO-DFP has enhanced selectivity for estrogen receptor alpha-positive (ERα+) cancer cells with a wider selectivity window than ErSO.ErSO-DFP displays antitumor activity and leads to profound regression of MCF-7 tumors in mice model[1]. | | References | [1]. Matthew W Boudreau, et al. Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer. J Med Chem. 2022 Mar 10;65(5):3894-3912. |
| | 2H-Indol-2-one, 3-(4,4-difluoro-1-piperidinyl)-1,3-dihydro-3-(4-hydroxyphenyl)-7-(trifluoromethyl)-, (3R)- Preparation Products And Raw materials |
|